Do you want to read an article? Please log in or register.
Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma
Lung, Respiratory and Thoracic Cancer
Related content
Lung, Respiratory and Thoracic Cancer
Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early stage squamous cell lung carcinoma
J Thorac Oncol.
Yu H, Chen Z, Ballman K, Watson MA, Govindan R, Lanc I, Beer DG, Bueno R, Chirieac L, Chui MH, Chen G, Franklin WA, Gandara DR, Genova C, Brovsky K, Harpole D, Joshi M, Merrick DT, Richards W, Rivard CJ, Tsao MS, van Bokhoven A, Shepherd FA, Hirsch FR
doi: 10.1016/j.jtho.2018.09.006.
Lung, Respiratory and Thoracic Cancer
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma
doi: 10.1016/j.jtho.2018.08.007.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Cancer Discov
Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM
doi: 10.1158/2159-8290.CD-21-0331
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Cancer Discov
Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM
doi: 10.1158/2159-8290.CD-21-0331
Lung, Respiratory and Thoracic Cancer
State of the Art: Advances in Malignant Pleural Mesothelioma in 2017
J Thorac Oncol.
McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK, Reungwetwattana T, Mao W, Pass HI, Carbone M, Yang H, Peikert T
doi: 10.1016/j.jtho.2018.02.021.
RECOMMENDED
Genitourinary Cancer
Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy
doi: 10.1016/j.eururo.2018.06.045.
Lung, Respiratory and Thoracic Cancer
Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma
J Thorac Oncol
Yeap BY, De Rienzo A, Gill RR, Oster ME, Dao MN, Dao NT, Levy RD, Vermilya K, Gustafson CE, Ovsak G, Richards WG, Bueno R
doi: 10.1016/j.jtho.2021.06.014
Lung, Respiratory and Thoracic Cancer
PD-L1 expression in large cell neuroendocrine carcinoma of the lung
Lung Cancer.
Eichhorn F, Harms A, Warth A, Muley T, Winter H, Eichhorn ME
doi: 10.1016/
WCLC 2020
Lung, Respiratory and Thoracic Cancer
Malignant Mesothelioma
Fennel D et al. 2021. Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial. Oral presentation presented at: WCLC 2020; 28−31 January 2021.